Oxford-based Refeyn Ltd, which develops instrumentation for the disruptive new life science technology mass photometry, has successfully completed its Series A funding round.
The oversubscribed Series A financing was led by USA-based Northpond Ventures and was strongly supported by existing investors including Oxford Sciences Innovation, Foresight Williams Technology, the University of Oxford, and new investors Horizons Ventures.
Refeyn was spun out of Oxford University in 2018 with the goal to make mass photometry available to the scientific community, The opportunity around our unique technology has attracted a passionate team of people who collectively have spent decades in the development and commercialization of microscopes and other analytical instrumentation.
Refeyn’s flagship product, the Refeyn OneMP Mass Photometer, can rapidly and simply measure the mass of individual molecules in solution, transforming the ability to characterise the composition, structure and dynamics of biomolecules in their native environment. The OneMP is currently used across a range of high-value research applications, including analysing protein-protein interactions, and the development of cell & gene therapies.
Proceeds from the funding round will support the introduction of Refeyn’s next-generation instruments, building on the rapid market adoption of the OneMP by both academic and industrial institutions.
Jonathan Flint, Chair of Refeyn Ltd, said: “Refeyn was founded on the belief that mass photometry has the potential to offer transformational analytical information to the scientific community, and we are delighted by the endorsement from Northpond and our Series A investors in supporting this financing. It is a testament to the progress of the technology and the team to date, and I look forward to the new frontiers for mass photometry that Refeyn will open over the coming years.”